Adverum Biotechnologies Inc.
| NASDAQ: ADVM |
| Healthcare / Biotechnology / USA |
| 2.24 | -0.0100 | -0.44% | Vol 375.72K | 1Y Perf -80.12% |
| Sep 23rd, 2021 13:32 DELAYED |
| BID | 2.24 | ASK | 2.25 | ||
| Open | 2.26 | Previous Close | 2.25 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 5.00 | Analyst Rating | Strong Buy 1.38 | |
| Potential % | 123.21 | Finscreener Ranking | ★★★★ 54.35 | |
| Insiders Trans % 3/6/12 mo. | -/100/27 | Value Ranking | ★★★★ 55.74 | |
| Insiders Value % 3/6/12 mo. | -/100/39 | Growth Ranking | ★★ 46.50 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/100/51 | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.34 | Earnings Rating | Strong Sell | |
| Market Cap | 219.80M | Earnings Date | 4th Nov 2021 | |
| Alpha | 0.02 | Standard Deviation | 0.28 | |
| Beta | 1.13 |
Today's Price Range 2.222.28 | 52W Range 2.0714.79 | 5 Year PE Ratio Range -7.30-1.30 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.90% | ||
| 1 Month | -4.26% | ||
| 3 Months | -38.52% | ||
| 6 Months | -77.16% | ||
| 1 Year | -80.12% | ||
| 3 Years | -61.86% | ||
| 5 Years | -46.30% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -37.80 | |||
ROE last 12 Months | -40.80 | |||
ROA (5Y Avg) | -20.13 | |||
ROA last 12 Months | -31.56 | |||
ROC (5Y Avg) | -36.13 | |||
ROC last 12 Months | -33.59 | |||
Return on invested Capital Q | -9.30 | |||
Return on invested Capital Y | -34.96 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.60 | ||||
| 0.60 | ||||
| 29.31 | ||||
| 242.90 | ||||
| -2.00 | ||||
| -1.10 | ||||
| 0.60 | ||||
| 3.86 | ||||
| -7 626 250.00 | ||||
| Forward PE | -1.57 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 18.50 | ||||
| 18.80 | ||||
| 0.25 | ||||
| 0.34 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -1 834.20 | ||||
| -1 772.60 | ||||
| -13 415.90 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.50M | ||||
| 0.08 | ||||
| -48.48 | ||||
| -27.54 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2021 | -0.37 | -0.45 | -21.62 |
| Q01 2021 | -0.38 | -0.29 | 23.68 |
| Q04 2020 | -0.32 | -0.39 | -21.88 |
| Q03 2020 | -0.35 | -0.31 | 11.43 |
| Q02 2020 | -0.30 | -0.36 | -20.00 |
| Q01 2020 | -0.27 | -0.31 | -14.81 |
| Q04 2019 | -0.31 | -0.29 | 6.45 |
| Q03 2019 | -0.27 | -0.25 | 7.41 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2021 QR | -0.40 | -17.65 | Negative |
| 12/2021 QR | -0.36 | 12.20 | Positive |
| 12/2021 FY | -1.54 | -4.76 | Negative |
| 12/2022 FY | -1.47 | 12.50 | Positive |
| Next Report Date | 4th Nov 2021 |
| Estimated EPS Next Report | -0.40 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 375.72K |
| Shares Outstanding | 98.13M |
| Shares Float | 92.40M |
| Trades Count | 1.87K |
| Dollar Volume | 9.19M |
| Avg. Volume | 1.93M |
| Avg. Weekly Volume | 2.94M |
| Avg. Monthly Volume | 1.73M |
| Avg. Quarterly Volume | 1.96M |
Adverum Biotechnologies Inc. (NASDAQ: ADVM) stock closed at 2.25 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 541.98K shares and market capitalization of 219.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Adverum Biotechnologies Inc. CEO is Laurent Fischer.
The one-year performance of Adverum Biotechnologies Inc. stock is -80.12%, while year-to-date (YTD) performance is -79.24%. ADVM stock has a five-year performance of -46.3%. Its 52-week range is between 2.07 and 14.79, which gives ADVM stock a 52-week price range ratio of 1.34%
Adverum Biotechnologies Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 0.60, a price-to-sale (PS) ratio of 29.31, a price to cashflow ratio of 242.90, a PEG ratio of 2.32, a ROA of -31.56%, a ROC of -33.59% and a ROE of -40.80%. The company’s profit margin is -%, its EBITDA margin is -1 772.60%, and its revenue ttm is $7.50 Million , which makes it $0.08 revenue per share.
Of the last four earnings reports from Adverum Biotechnologies Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Adverum Biotechnologies Inc.’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for Adverum Biotechnologies Inc. is Strong Buy (1.38), with a target price of $5, which is +123.21% compared to the current price. The earnings rating for Adverum Biotechnologies Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Adverum Biotechnologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Adverum Biotechnologies Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.67, ATR14 : 0.14, CCI20 : -61.95, Chaikin Money Flow : -0.02, MACD : -0.07, Money Flow Index : 56.59, ROC : -3.85, RSI : 43.85, STOCH (14,3) : 31.91, STOCH RSI : 0.69, UO : 45.32, Williams %R : -68.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Adverum Biotechnologies Inc. in the last 12-months were: Dawn Svoronos (Buy at a value of $200 338), Laurent Fischer (Buy at a value of $395 941), Leone Patterson (Sold 25 066 shares of value $353 435 ), Patrick C. Machado (Buy at a value of $214 370)
Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.
CEO: Laurent Fischer
Telephone: +1 650 659-9323
Address: 800 Saginaw Drive, Redwood CIty 94063, CA, US
Number of employees: 114
